Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
Saved in:
Main Authors: | Hedi Schelleman (Author), Rudy Dupree (Author), Finn B Kristensen (Author), Wim Goettsch (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2015-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
by: Krzysztof Lach, et al.
Published: (2017) -
Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
by: Ting Wang, et al.
Published: (2022) -
Bridging the Gap: Why Strength and Conditioning Practitioners and Researchers should Collaborate
by: Andrew Langford, et al.
Published: (2020) -
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
by: Thomas Desmet, et al.
Published: (2024) -
Why should security aspects be more seriously considered in development of Serbian tourism industry?
by: Radović Vesela, et al.
Published: (2016)